Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | DTYMK | P23919 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8022167 | 0.85 | MEN1 (0.66) | MEN1KMT2ADTYMKALDH1A1HPGD | |
| SCHEMBL7833153 | 0.84 | HPGD (0.70) | HPGD | |
| SCHEMBL7839293 | 0.82 | TYMP (0.52) | MEN1KMT2AALDH1A1HPGDCMA1 | |
| SCHEMBL12501015 | 0.82 | MEN1 (0.49) | MEN1KMT2AALDH1A1HPGDCMA1 | |
| SCHEMBL12501006 | 0.82 | KMT2A (0.66) | MEN1KMT2ADTYMKALDH1A1CYP1A2 | |
| SCHEMBL1717207 | 0.81 | MEN1 (0.78) | MEN1KMT2ADTYMKCYP1A2CYP2C19 | |
| SCHEMBL12410767 | 0.81 | MMP13 (0.50) | MEN1KMT2AALDH1A1HPGDCMA1 | |
| SCHEMBL12410775 | 0.80 | MEN1 (0.47) | MEN1KMT2AALDH1A1HPGDCMA1 | |
| SCHEMBL7830417 | 0.79 | L3MBTL1 (0.64) | MEN1KMT2AALDH1A1HPGDCMA1 | |
| SCHEMBL17243375 | 0.78 | MMP13 (0.50) | MEN1KMT2AALDH1A1HPGDCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450343-B2 | Gamma secretase modulators | SCHERING CORPORATION | 2013-05-28 | — | — | US | disclosed |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-27 | — | — | US | disclosed |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2012-09-20 | — | — | US | disclosed |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | Merck, Sharp & Dohme, Corp. | 2012-09-13 | — | — | US | disclosed |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | RESPROTECT GMBH (DE) | 2011-07-07 | — | — | US | disclosed |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | SCHERING CORPORATION | 2011-02-03 | — | — | US | disclosed |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2011-01-20 | — | — | US | disclosed |
| WO-2010147969-A2 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147975-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010147973-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2010-12-23 | — | — | WO | disclosed |
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2010-11-25 | — | — | US | disclosed |
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | MERCK SHARP & DOHME CORP. | 2010-11-25 | — | — | US | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| WO-2009076337-A1 | GAMMA SECRETASE MODULATORS | SCHERING CORPORATION (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298359-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MEN1 3833/4885KMT2A 3472/4885DTYMK 2399/4885 |
| US-20120232108-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MEN1 3454/4885KMT2A 3709/4885DTYMK 2146/4885 |
| US-20110166096-A1 | URACIL DERIVATIVES AND USE THEREOF | TYMP, UNG, DPYD | MEN1 2207/4885KMT2A 3185/4885DTYMK 49/4885 |
| US-20120245158-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MEN1 3454/4885KMT2A 3709/4885DTYMK 2146/4885 |
| US-20100298372-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MEN1 3513/4885KMT2A 3849/4885DTYMK 1995/4885 |
| US-20110027264-A1 | GAMMA SECRETASE MODULATORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | BACE1, BACE2, PSEN1 | MEN1 3855/4885KMT2A 3325/4885DTYMK 1638/4885 |
| US-20120238546-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MEN1 3509/4885KMT2A 3871/4885DTYMK 2040/4885 |
| US-20110015190-A1 | GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | MEN1 3833/4885KMT2A 3472/4885DTYMK 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.